Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
LE.1.3.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XDR.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.49.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EG.5.1.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
HV.1.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.16.11NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.15.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
GK.1.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JD.1.1.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.441NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.509NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.293NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.225NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.637NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.39 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.26 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.103 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.3 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.18.7NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.52NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.42NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KB.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.14NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
MJ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.1.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.39.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.58.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.18.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LF.4.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XDK.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
MB.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LE.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LF.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
MD.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LP.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
DL.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.1.15NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.529 (Omicron)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BF.41.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.396NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.595.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.311NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.369NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.367NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.595NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.240NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used